From missed doses to missed refills to misunderstood instructions, the reasons for patient non-adherence to therapies are lengthy and varied. For...
Thanks to a fortunate confluence of focused advocacy, advances in research, and breakthroughs in gene therapy, a much more hopeful era of treatment for...
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease and the most common type of idiopathic interstitial lung disease. IPF...
We’re proud to introduce a few members of Orsini’s team of specialty pharmacists, the engine that drives our patient-centric organization. As we shared...
At a specialty pharmacy, all roads lead to the pharmacist. Pivotal to ensuring effective management of drugs for complex conditions, specialty...
Rare diseases impact individuals and families worldwide. We are honored to participate in Rare Disease Day to help raise awareness for patients living...
Hereditary ATTR amyloidosis (hATTR) is a rare, debilitating genetic condition affecting approximately 50,000 people worldwide. hATTR is characterized...
While it may seem as if 30 million Americans living with more than 7,000 distinct and rare medical conditions have little in common, there is much that...
Enzyme replacement therapy (ERT) is a treatment where replacement enzymes are utilized for patients who suffer from rare and complex conditions...
In the past 18 months, perhaps no advice to prevent the spread of COVID-19 has been more widely promoted and easier to implement than the act of...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
![[Whitepaper] Payor Considerations When Choosing a Specialty Pharmacy](https://no-cache.hubspot.com/cta/default/7642930/d6329582-47a1-404d-b2a8-63c2637a9807.png)